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Inactivation of the tumor suppressor p53 is one of the
leading causes of cancer as p53 inactivation via somatic
mutations occurs in 50% of human cancers and sometimes
in fibroblasts within the tumor microenvironment (TME).
Recent studies by our laboratory and others suggest that
p53 inactivation promotes a pro-inflammatory host micro-
environment - elevated serum inflammatory cytokines/
chemokines, enhanced Th17 cells, and augmented differ-
entiation of myeloid cells, including myeloid derived sup-
pressors (MDSCs). As chronic inflammation plays a vital
role in tumor initiation, progression, and metastases, we
hypothesized that p53inactivation in the TME favors
tumorigenesis by promoting inflammation. To test our
hypothesis and elucidate the cellular and molecular
mechanisms by which p53 inactivation augments pro-
inflammation and tumor progression, we compared the
growth of subcutaneously inoculated B16F1 melanoma
with a functional p53 in p53null and WT mice. As
expected, tumor growth in p53nullmice was greatly accel-
erated. Remarkably, the accelerated tumor growth in
p53null hosts was associated with an extensive expansion
of stromal populations, including various myeloid popula-
tions, as well as non-hematopoietic reticular fibroblastic
cells (FRC) reminiscent of stromal cells of the secondary
lymphoid organs (SLO), both within the TME and the
secondary lymphoid tissues. Further cellular and molecu-
lar analyses revealed that these CD106hiCD54+GP38
+Sca-1lo/- FRCs, especially from p53null hosts, expressed
high levels of pro-inflammatory cytokines/chemokines and
immunosuppressive mediators that supported the survival
and proliferation of various myeloid populations, including
CD11b+Gr-1+ myeloid-derived suppressor cells (MDSCs).
Together, our results suggest that p53null stroma is highly
immunosuppressive, which modulates host immune-
microenvironment via cytokine/chemokine and stroma-
immune cell interaction and promotes tumor progression.
This study underscores the immunological function of p53
in tumor suppression and broadens our appreciation of
the p53 as a guardian and gatekeeper not only via inducing
apoptosis and cellular senescence, but also via regulating
the immunological microenvironment.
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